February 7, 2024

Profitability and Expansion: 3 Impressive Companies Profitability and Expansion: 3 Impressive Companies

We continue to navigate the Q4 earnings cycle, witnessing many companies unveiling their quarterly results daily. It’s clear that many companies have delivered positive surprises, with three standout companies experiencing meaningful margin expansion during this period.

In particular, Netflix NFLX, Procter & Gamble PG, and Meta Platforms META have all demonstrated pleasing results, reflecting improved profitability. For those eager to dive into the earnings momentum, let’s delve into each company’s performance.

Netflix: Streaming to Success

The streaming giant Netflix has enjoyed a surge in positive earnings estimate revisions, securing a Zacks Rank #1 (Strong Buy).

Image Source: Zacks Investment Research

Notably, operating income soared to $1.5 billion, up from $0.5 billion, elevating the operating margin to 17% from 7% year-over-year.

The period also saw a remarkable 13.1 million subscriber additions, bypassing the consensus estimate of 8.8 million. The company has consistently exceeded subscriber expectations.

Image Source: Zacks Investment Research

Meta Platforms: Surging Forward

Meta Platforms has consistently outperformed earnings expectations, surpassing the consensus EPS estimates by an average of 20% in its last four releases. Impressively, the company’s operating margin soared to 41%, up from 20% year-over-year.

The latest report unveiled a 25% year-over-year revenue increase and an exceptional 77% surge in EPS. The 25% revenue jump marked the highest growth rate in eight quarters.

Image Source: Zacks Investment Research

To add to its exceptional results, the company announced its first-ever dividend, payable on March 26^th to stockholders of record as of February 22^nd end of trading.

Procter & Gamble: Boosting Profitability

Procter & Gamble surpassed the Zacks Consensus EPS estimate by 8% and reported revenue slightly below expectations, both exceeding the year-ago figures. The company’s gross margin of 52.7% was significantly higher than the year-ago figure of 47.5%.

See also <!DOCTYPE html><html><head> <title>Navigating the September Stock Market Blues with Medical Stocks</title></head><body><h2>Understanding the September Stock Market Trends</h2><p>Historically, September has proven to be a tumultuous month for stock investors. Dubbed the September Effect, this phenomenon is characterized by increased market volatility and lower overall stock performance, often influenced by economic policy decisions and higher trading volumes post-summer.</p><h2>Why Medical Stocks Might Be Your Best Bet</h2><p>During seasons of heightened market uncertainty, many investors turn to defensive sectors such as healthcare for stability and protection against market downturns. As the demand for essential services remains consistent, medical stocks are often viewed as a safe haven amid the September storm.</p><h2>DaVita: A Strong Contender</h2><p>DaVita, a leading provider of dialysis services, has been turning heads with its impressive stock performance, soaring over 40% year-to-date. With a Zacks Rank #1 (Strong Buy) and attractive valuation metrics, DaVita seems well-positioned to weather the storm of September. Analysts predict steady revenue growth for the company in the upcoming fiscal years, adding to its appeal for investors seeking stability.</p><h2>HCA Healthcare: Riding the Wave</h2><p>Another top player in the medical stocks arena is HCA Healthcare, the largest operator of non-governmental acute care hospitals in the US. With a Zacks Rank #1 (Strong Buy) and a robust earnings outlook, HCA Healthcare has seen its stock price climb over 40% this year. The company's focus on value and consistent revenue expansion make it a compelling choice for investors looking for solid returns.</p><h2>Eli Lilly: Innovating for Success</h2><p>Eli Lilly has been making waves in the pharmaceutical industry with its innovative drug pipeline catering to the needs of Type 2 diabetics. With a Zacks Rank #2 (Buy) and a strong market presence in the diabetes and obesity treatment space, Eli Lilly is well-positioned for growth in the coming years. The company's aggressive growth projections and positive sentiment around its products make it a promising option for investors seeking exposure to the healthcare sector.</p><h2>Looking Ahead</h2><p>As investors brace themselves for the uncertainties of September, the allure of medical stocks shines bright. With companies like DaVita, HCA Healthcare, and Eli Lilly displaying resilience and growth potential, these stocks may serve as anchors in an otherwise turbulent market. Keeping a keen eye on market trends and leveraging the stability of healthcare stocks could be the winning strategy for navigating the September Effect.</p></body></html><!DOCTYPE html><html><head> <title>Exploring Top Medical Stocks Amid Market Volatility</title></head><body> Unveiling Top Medical Stocks Amid Market Uncertainty

Subsequently, the company raised its FY24 core net EPS growth to a range of 8% – 9%, up from the previous expectation of 6% – 9%. This positive trajectory injected bullish sentiment into the company’s shares.

Image Source: Zacks Investment Research

Conclusion

An auspicious operating environment has led to increased profitability for many companies, propelling shares to surge post-earnings throughout the 2023 Q4 cycle thus far. For investors on the lookout for companies enjoying margin expansion, each of the three companies – Netflix NFLX, Procter & Gamble PG, and Meta Platforms META – have demonstrated an inspiring improvement in their profitability.

Zacks Investment Research

5 Stocks Our Experts Predict Could Double In the Next Year

By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.